Pharma/fine chemicals roundup—19 March
8:40 AM MDT | March 19, 2013 | By DEEPTI RAMESH
Mitsubishi Chemical subsidiary partners with Indian pharma ingredients firm
Neuland Laboratories (Hyderabad, India), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract manufacturing services, says it has entered into a manufacturing collaboration with API Corp. (Tokyo), a subsidiary of Mitsubishi Chemical that produces APIs, intermediates, and investigational new drugs, along with fine chemicals and reagents. API Corp., under the terms of the agreement, is making an investment in Neuland’s facilities that will provide API Corp. with dedicated capacity for meeting the needs of its customers. The facilities will be operated by Neuland employees and the two companies will share oversight and management responsibilities.
Merck & Co. to shut API plant in Ireland
Merck & Co. (Whitehouse Station, NJ) plans to shut down its active pharmaceutical ingredient (API) manufacturing plant at Rathdrum, Ireland, by 2015, and 280 jobs will be cut as a result, say press reports. The company does not plan to outsource production. Production from the Rathdrum plant will be shifted to the company's other facilities in Ireland and Singapore, reports say.
The Rathdrum site was established in 1961 as Loftus Bryan Chemicals, and was acquired by Schering-Plough in 1980 to support the development and supply of APIs to global markets. The site became a part of Merck & Co. through the 2009 acquisition of Schering-Plough for about $41.1 billion. The Rathdrum site currently supplies over 10 APIs, Merck & Co. says.
Founder of Dr. Reddy’s Laboratories dies at 72
Anji Reddy, founder and chairman of Dr. Reddy’s Laboratories (Hyderabad, India), passed away on 15 March at the age of 72. Anji Reddy graduated from the Bombay University with specialization in pharmaceutical science and fine chemicals, and obtained his PhD in chemical engineering from the National Chemical Laboratory (Pune, India). He founded Dr. Reddy’s in 1984 and it became the first pharmaceutical company in India to initiate basic drug discovery research in 1993. He also set up the Institute of Life Sciences at Hyderabad, which is a public-private partnership with the local government for carrying out research in life sciences. Dr. Reddy’s has the second-largest active pharmaceutical ingredient (API) business in the world in terms of sales, after Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel).
DSM signs supply agreement with Eisai
DSM Pharmaceutical Products (Parsippany, NJ), the custom manufacturing and technology business of DSM, says it has signed a three-year master supply agreement with Eisai Inc. (Woodcliff Lake, NJ), a subsidiary of Eisai (Tokyo), for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Financial terms were not disclosed. DSM will be a supplier for eribulin mesylate to the US market; commercial production is expected to start later this year. DSM operates a finished dosage facility at Greenville, NC, with capabilities in aseptic filling of liquid and freeze-dried cytotoxic and noncytotoxic steriles, the manufacture of tablets and capsules, pharmaceutical development services, and clinical trial materials manufacturing for solid and injectable forms.
Beyond IHS Chemical Week
World API market growth slows
Cost competition and the financial crisis have slowed the growth of the global API market over the past four years, according to new data released by the CPA, the Italian Chemical Pharmaceutical Association.
Connect with IHS Chemical Week
Our related sites